Dementia - Pipeline Review, H2 2020

August 2020 | 537 pages | ID: D70009828BBEN
Global Markets Direct

Abstracts

Dementia - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2020, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 22, 25, 2, 67, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 1, 1, 12, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Dementia - Overview
Dementia - Therapeutics Development
Dementia - Therapeutics Assessment
Dementia - Companies Involved in Therapeutics Development
Dementia - Drug Profiles
Dementia - Dormant Projects
Dementia - Discontinued Products
Dementia - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dementia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..2), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020 (Contd..2), H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Dementia - Pipeline by AbbVie Inc, H2 2020
Dementia - Pipeline by Acadia Pharmaceuticals Inc, H2 2020
Dementia - Pipeline by Actinogen Medical Ltd, H2 2020
Dementia - Pipeline by AcuraStem Inc, H2 2020
Dementia - Dormant Projects, H2 2020
Dementia - Discontinued Products, H2 2020
Dementia - Discontinued Products, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dementia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

AbbVie Inc
Acadia Pharmaceuticals Inc
Actinogen Medical Ltd
AcuraStem Inc
Adamed Sp zoo
ADEL Inc
AFFiRiS AG
AgeneBio Inc
Aibios Co Ltd
Alector Inc
Alkermes Plc
Allergan Ltd
AlphaCognition Inc
Alterity Therapeutics Ltd
Anavex Life Sciences Corp
Annovis Bio Inc
Applied Genetic Technologies Corp
Aprinoia Therapeutics Inc
AriBio
Arkuda Therapeutics Inc
Arvinas Inc
Asceneuron SA
Avanir Pharmaceuticals Inc
Axon Neuroscience SE
Axovant Gene Therapies Ltd
Axsome Therapeutics Inc
Bicycle Therapeutics Plc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Cellular Biomedicine Group Ltd
Cennerv Pharma (S) Pte Ltd
Cerevel Therapeutics LLC
ChunLab Inc
Cortice Biosciences Inc
CSPC NBP Pharmaceutical Co Ltd
Curyx Bio Inc
Cyclerion Therapeutics Inc
Dadang & BIO Co Ltd
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dongkook Pharmaceutical Co Ltd
Dr. August Wolff GmbH & Co KG Arzneimittel
Echo Pharmaceuticals BV
EIP Pharma LLC
Eisai Co Ltd
Eli Lilly and Co
Ensol Biosciences Inc
Enterin Inc
EVER Neuro Pharma GmbH
Galimedix Therapeutics Ltd
Gismo Therapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
GW Pharmaceuticals Plc
HanAll Biopharma Co Ltd
Hemostemix Inc
HSRx Group
Hyundai Pharma Co Ltd
Immungenetics AG
ImStar Therapeutics Inc
Inhibikase Therapeutics Inc
IntraBio Ltd
IRLAB Therapeutics AB
Johnson & Johnson
Kogenix Therapeutics Inc
Korea Pharma Co Ltd
Kwang Dong Pharmaceutical Co Ltd
Lachesis Biosciences Ltd
Luye Pharma Group Ltd
Mediforum Pharmaceutical Inc
MediPost Co Ltd
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
MGC Pharmaceuticals Ltd
Neuraltus Pharmaceuticals Inc
Neurimmune Holding AG
Neurokine Therapeutics
NeuroScientific Biopharmaceuticals Ltd
NeuroTau Inc
NLS Pharma Group
Novartis AG
Oligomerix inc
Orchard Therapeutics Plc
Oryzon Genomics SA
Otsuka Pharmaceutical Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Palisades Therapeutics
Park Active Molecules
Passage Bio Inc
Plico Biotech Inc
Prediction BioSciences SAS
Prevail Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Psy Therapeutics Inc
QurAlis Corporation
Reborna Biosciences Inc
Resverlogix Corp
Reven Pharmaceuticals Inc
Samus Therapeutics Inc
Sinfonia Biotherapeutics Inc
SK Chemicals Co Ltd
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Suven Life Sciences Ltd
SyneuRx International Corp
T3D Therapeutics Inc
TauRx Therapeutics Ltd
Theranexus SAS
Time Therapeutics Inc
Towa Pharmaceutical Co Ltd
Tranquis Therapeutics Inc
UniQure NV
Verge Genomics Inc
Voyager Therapeutics Inc
Wave Life Sciences Ltd
WhanIn Pharmaceutical Co Ltd